- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eli Lilly Gets CDSCO Panel Nod To Market Mirikizumab for ulcerative colitis in adults
New Delhi: Pharmaceutical major Eli Lilly has got marketing authorization from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) for Mirkizumab Injection 300mg/15mL solution in vial and 100mg/mL solution in Prefilled Syringe (PFS) indicated for the treatment of moderate to severe active ulcerative colitis in adult.This came after the...
New Delhi: Pharmaceutical major Eli Lilly has got marketing authorization from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) for Mirkizumab Injection 300mg/15mL solution in vial and 100mg/mL solution in Prefilled Syringe (PFS) indicated for the treatment of moderate to severe active ulcerative colitis in adult.
This came after the drug maker Eli Lilly presented the proposal to import and market Mirikizumab Injection 300mg/15mL solution in vial and 100mg/mL solution in PFS indicated for the treatment of moderate to severe active ulcerative colitis in adults based on the results of global clinical trials conducted by the firm including the Indian population.
The committee noted that the drug is approved in USA, Europe, Canada, Japan, Australia and other countries.
Mirikizumab is a monoclonal antibody directed against the p19 subunit of human interleukin-23 (IL-23). The binding of mirikizumab to its target inhibits the interaction between IL-23 and the IL-23 receptor, thereby normalizing the overproduction of effector cytokines driving the pathogenesis of inflammatory diseases, including ulcerative colitis.
Mirikizumab is an anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis.
Mirikizumab-mrkz injection is used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults.
At the recent SEC meeting for Gastroenterology and Hepatology held on 13th March 2024, the expert panel reviewed the proposal presented by Eli Lilly to import and market Mirikizumab Injection 300mg/15mL solution in vial and 100mg/mL solution in PFS indicated for the treatment of moderate to severe active ulcerative colitis in adults based on the results of global clinical trials conducted by the firm including the Indian population.
After detailed deliberation, the committee recommended a grant of marketing authorization to the firm for Mirkizumab Injection 300mg/15mL solution in vial and 100mg/mL solution in PFS subject to the condition that the firm should conduct Phase IV clinical trial in the country.
Accordingly, the expert panel suggested that the firm should submit a Phase IV clinical trial protocol to CDSCO within 3 months of marketing approval.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751